Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy
Haemophilia · 2024-05 · 30 (3) · 709-719
DOI: 10.1111/hae.14977 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Haemophilia, online erschienen am 10.03.2024. Verfasst von Robbin Itzler und 7 weiteren Autor:innen. Beteiligte Einrichtung: CSL Behring, King of Prussia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Quality of Life, Hemophilia B, Genetic Therapy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Introduction
For people with haemophilia B (PwHB), bleeding may occur despite prophylaxis, negatively affecting health‐related quality of life (HRQoL). The pivotal phase 3 HOPE‐B trial investigating the adeno‐associated virus gene transfer product, etranacogene dezaparvovec (EDZ), demonstrated sustained factor IX (FIX) activity and bleed protection in PwHB with baseline FIX levels ≤2%.
Aim
Assess how EDZ affects HRQoL in HOPE‐B trial participants.
Methods
HRQoL was evaluated using generic and disease‐specific patient reported outcomes (PROs) including the EQ‐5D‐5L and the Hem‐A‐QoL questionnaires. Mean domain and total scores were compared 6 months pre‐ and the first 2 years post‐EDZ administration using repeated measures linear mixed models. The percentage of participants with minimal clinically important improvements in HRQoL was also evaluated.
Results
Two years post‐EDZ, there were nominally significant increases in the least squares (LS) mean score for the EQ‐5D‐5L Index Value (.04; p = .0129), reflecting better HRQoL. Nominally significant decreases in the LS mean scores, reflecting better HRQoL, were also found for the Hem‐A‐QoL total score (−6.0; p < .0001) and the Treatment (−13.94; p < .0001), Feelings (−9.01; p < .0001), Future (−6.45; p = .0004) and Work/School (−5.21; p = .0098) domains. The percentage of participants with ≥15‐point improvement ranged from 45.83% (95% CI: 31.37%, 60.83%) for Treatment to 13.89% (95% CI: 4.67%, 29.50%) for Family Planning. Results were similar for Year 1.
Conclusion
In conclusion, gene therapy with EDZ improved HRQoL in the first and second years in several Hem‐A‐QoL domains, including Treatment, Feelings, Work/School and Future domains, whereas improvement in other aspects of HRQoL were not demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CSL Behring, King of Prussia, Pennsylvania, USA.
- Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
- Everest Clinical Research, New Jersey, USA.
- National Bleeding Disorders Foundation, New York, New York, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Tyler W Buckner, Frank W G Leebeek, Michael Recht, Steven W Pipe
Förderung
- CSL Behring
Zitieren
APA
Itzler, R., Buckner, T. W., Leebeek, F. W. G., Miller, J., Recht, M., Drelich, D., Monahan, P. E., & Pipe, S. W. (2024). Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia, 30(3), 709-719. https://doi.org/10.1111/hae.14977
Vancouver
Itzler R, Buckner TW, Leebeek FWG, Miller J, Recht M, Drelich D, et al. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia. 2024;30(3):709-719. doi:10.1111/hae.14977
BibTeX
@article{Itzler2024,
author = {Itzler, Robbin and Buckner, Tyler W and Leebeek, Frank W G and Miller, Joel and Recht, Michael and Drelich, Douglass and Monahan, Paul E and Pipe, Steven W},
title = {Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy},
journal = {Haemophilia},
year = {2024},
volume = {30},
number = {3},
pages = {709--719},
doi = {10.1111/hae.14977}
}
EUVIMED